Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer
dc.contributor.author | Leko, Vid | |
dc.contributor.author | McDuffie, Lucas A. | |
dc.contributor.author | Zheng, Zhili | |
dc.contributor.author | Gartner, Jared J. | |
dc.contributor.author | Prickett, Todd D. | |
dc.contributor.author | Apolo, Andrea B. | |
dc.contributor.author | Agarwal, Piyush K. | |
dc.contributor.author | Rosenberg, Steven A. | |
dc.contributor.author | Lu, Yong-Chen | |
dc.contributor.department | Surgery, School of Medicine | en_US |
dc.date.accessioned | 2020-11-09T19:36:25Z | |
dc.date.available | 2020-11-09T19:36:25Z | |
dc.date.issued | 2019-06-15 | |
dc.description.abstract | Immune checkpoint inhibitors (ICIs) are effective in treating a variety of malignancies, including metastatic bladder cancer. A generally accepted hypothesis suggests that ICIs induce tumor regressions by reactivating a population of endogenous tumor-infiltrating lymphocytes (TILs) that recognize cancer neoantigens. Although previous studies have identified neoantigen-reactive TILs from several types of cancer, no study to date has shown whether or not neoantigen-reactive TILs can be found in bladder tumors. To address this, we generated TIL cultures from patients with primary bladder cancer and tested their ability to recognize tumor-specific mutations. We found that CD4+ TILs from one patient recognized mutated C-terminal binding protein 1 (CTBP1Q277R) in an MHC class II-restricted manner. This finding suggests that neoantigen-reactive TILs reside in bladder cancer, which may help explain the effectiveness of immune checkpoint blockade in this disease, and also provides a rationale for the future use of adoptive T-cell therapy targeting neoantigens in bladder cancer. | en_US |
dc.eprint.version | Author's manuscript | en_US |
dc.identifier.citation | Leko, V., McDuffie, L. A., Zheng, Z., Gartner, J. J., Prickett, T. D., Apolo, A. B., Agarwal, P. K., Rosenberg, S. A., & Lu, Y.-C. (2019). Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer. The Journal of Immunology, 202(12), 3458–3467. https://doi.org/10.4049/jimmunol.1801022 | en_US |
dc.identifier.issn | 0022-1767, 1550-6606 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/24348 | |
dc.language.iso | en_US | en_US |
dc.publisher | American Association of Immunologists | en_US |
dc.relation.isversionof | 10.4049/jimmunol.1801022 | en_US |
dc.relation.journal | The Journal of Immunology | en_US |
dc.source | PMC | en_US |
dc.subject | lymphocytes | en_US |
dc.subject | Primary Bladder Cancer | en_US |
dc.subject | Immune checkpoint inhibitors | en_US |
dc.subject | tumor-infiltrating lymphocytes | en_US |
dc.title | Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer | en_US |
dc.type | Article | en_US |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- nihms-1526911.pdf
- Size:
- 949.09 KB
- Format:
- Adobe Portable Document Format
- Description:
- Author's manuscript
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.99 KB
- Format:
- Item-specific license agreed upon to submission
- Description: